Last reviewed · How we verify
Autologous HB-adMSCs
At a glance
| Generic name | Autologous HB-adMSCs |
|---|---|
| Sponsor | Hope Biosciences LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
- A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy (PHASE1, PHASE2)
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" (PHASE2)
- Individual Patient Expanded Access IND for the Treatment of Stroke
- HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.
- Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury
- Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy
- An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous HB-adMSCs CI brief — competitive landscape report
- Autologous HB-adMSCs updates RSS · CI watch RSS
- Hope Biosciences LLC portfolio CI